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SUMMARY – Although total mesorectal excision reduces the local recurrence rate in compari-
son to other surgical approaches, the occurrence of local relapse is still common, especially in cases 
when there is malignant infiltration of the circumferential resection margin. Mesorectal fascia is an 
important prognostic and diagnostic factor and it may be argued that mesorectal fascia represents the 
circumferential resection margin if total mesorectal excision is used as a surgical approach. Tumor 
infiltration of mesorectal fascia warrants preoperative neoadjuvant therapy in order to reduce the risk 
of tumor relapse. The aim of this study was to show the importance of high-resolution phased-array 
magnetic resonance imaging (MRI) as a modality of choice in preoperative evaluation of the effects 
of neoadjuvant therapy on locally advanced rectal carcinoma. This prospective comparative study 
included 51 patients with locally advanced rectal carcinoma that infiltrated mesorectal fascia. All 
study patients underwent MRI scanning twice, i.e. before and after neoadjuvant chemoradiothera-
py. MRI results before and after neoadjuvant chemoradiotherapy were compared to evaluate regre-
ssion of tumor length and regression of tumor infiltration of mesorectal fascia. Gender distribution 
of 51 patients with rectal carcinoma subjected to neoadjuvant therapy was equal, and their average 
age was 51 (32-81) years. MRI results showed tumor regression from mesorectal fascia following 
chemoradiotherapy in 36 (70.5%) cases, and Wilcoxon test showed significant differences between 
pretherapeutic and post-treatment MRI findings (Z=-3.162, p=0.002) in the sense of regression of 
tumor infiltration of mesorectal fascia. In 41 (80.3%) cases there was a reduction of tumor length, 
where Wilcoxon test showed differences between pretherapeutic and post-treatment MRI findings 
(Z=-2.754, p=0.006) in the sense of tumor length reduction. The mean pretherapeutic tumor length 
was 5.4 (2.3-15) cm. The mean reduction of tumor length following chemoradiotherapy was 3.56 
(0.3-4.1) cm. In all 36 patients that had tumor-free mesorectal fascia following surgical treatment, 
the post-treatment MRI results were confirmed by histopathology. In conclusion, MRI is important 
for evaluation of tumor infiltration of mesorectal fascia, and is useful on patient selection for appro-
priate treatment for rectal carcinoma. MRI reliably evaluates the effects of neoadjuvant therapy, 
which contributes to better outcome of treatment for this disease. 
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Introduction
Rectal carcinoma is one of the most common car-
cinomas in Europe and the USA, with poor prognosis 
due to the high risk of local relapse and metastases1. 
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Although total mesorectal excision reduces the local 
recurrence rate to less than 10% when compared to 
other surgical approaches, the occurrence of local re-
lapse is still common, especially if circumferential re-
section margin from the tumor is involved2. Involve-
ment of the lateral or circumferential resection margin 
was the most important risk factor for local recurrence 
after rectal cancer surgery3, and is considerably more 
relevant than distal or proximal resection margins. 
Therefore, mesorectal fascia is an important prognos-
tic factor and it may be argued that mesorectal fascia 
represents the circumferential resection margin if to-
tal mesorectal excision is used as surgical approach.
The aim of this study was to show the importance 
of high-resolution phased-array magnetic resonance 
imaging (MRI) as a modality of choice to preopera-
tively evaluate the effects of neoadjuvant therapy on 
locally advanced rectal carcinoma.  
Patients and Methods 
This prospective comparative study included 51 
patients with locally advanced rectal carcinoma which 
infiltrated mesorectal fascia. All of the patients un-
derwent MRI scanning twice, i.e. before and after 
neoadjuvant chemoradiotherapy. The scanning was 
performed on a 1.5T scanner (Avanto Siemens, Er-
langen, Germany), 3-mm slice thickness, field of view 
160-200 mm, with the use of a pelvic phased-array 
surface RF coil. Lumen of the rectum was cleansed, 
free from intestinal content, and filled with ultra-
sound gel as intraluminal contrast agent. Intravenous 
application of contrast agent or antiperistaltic agent 
was not performed. MRI results before and after neo-
adjuvant chemoradiotherapy were compared in order 
to evaluate regression of rectal tumor. Evaluation pa-
rameters were regression of tumor length (because of 
proximal and distal resection margin) and regression 
of tumor infiltration of mesorectal fascia (because of 
lateral resection margin). Minimum tumor distance 
to mesorectal fascia -5 mm was taken as an indication 
of no involvement of mesorectal fascia. Post-treatment 
MRI results were compared with histopathologic 
finding.
Statistical program SPSS 15.0 (SPSS, Inc., Chi-
cago, IL, USA) and MedCalc® Statistical Software 
version were used on data processing. 
Results 
Statistical data showed that all 51 patients with 
carcinoma of the rectum that underwent neoadjuvant 
therapy were equally divided by gender and average 
age 51 (32-81) years. Histopathologic verification 
showed that all 51 (100%) patients had adenocarci-
noma; G2 stage was present in 39 (76.4%), G3 stage in 
12 (23.6%) and mucinous type in five (9.8%) patients. 
MRI results showed tumor regression from mesorec-
tal fascia following chemoradiotherapy in 36 (70.5%) 
cases, and Wilcoxon test showed significant differ-
ences between pre- and post-treatment MRI find-
ings  (Z=-3.162, p=0.002) in the sense of regression of 
tumor infiltration of mesorectal fascia. In 41 (80.3%) 
cases, there was a reduction of tumor length, and Wil-
coxon test showed differences between pre- and post-
treatment MRI findings (Z=-2.754, p=0.006) in the 
sense of tumor length reduction. The mean prethera-
peutic length of the tumor was 5.4 (2.3-15) cm. The 
mean reduction of tumor length following chemora-
diotherapy was 3.56 (0.3-4.1) cm. In all 36 patients 
that had tumor-free mesorectal fascia following neo-
adjuvant therapy and who became operable the post-
treatment results were compared with histopathologic 
findings. In all these patients, histopathologic find-
ings confirmed the post-treatment MRI findings. 
Discussion
As an aperistaltic organ, the rectum is suitable for 
application of radiotherapy. After surgical treatment 
for rectal carcinoma, patients are subjected to adjuvant 
chemoradiotherapy. Patients with locally advanced 
tumor also need preoperative neoadjuvant chemora-
diotherapy prior to surgery in order to reduce the size 
and stage of the tumor. Mesorectal fascia is an im-
portant prognostic and diagnostic marker, and tumor 
infiltration of mesorectal fascia warrants neoadjuvant 
therapy in order to prevent the occurrence of tumor 
relapse4-6. High-resolution MRI with use of phased 
coil is able to visualize the layers of the rectal wall, the 
mesorectal fascia, and to predict the depth of tumor 
invasion7,8. Mesorectal fascia is depicted as a thin, low-
signal-intensity structure that envelops the mesorec-
tum and surrounds the perirectal fat. If the distance of 
the tumor from mesorectal fascia is ≥5 mm, radiolo-
gist may consider the fascia uninvolved; if the distance 
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is 2-5 mm, the involvement is considered borderline; if 
it is ≤1 mm, mesorectal fascia is involved. Radiologist 
is assured that the mesorectal fascia is free from tu-
mor only when an intact rectal wall is detected9. Many 
randomized clinical studies indicate the importance 
of preoperative (neoadjuvant) and postoperative (ad-
juvant) chemoradiotherapy in decreasing the risk of 
local recurrence10-12. Neoadjuvant therapy is standard 
in the treatment of rectal carcinoma for locally ad-
vanced rectal carcinoma and cannot be compensated 
for by adjuvant therapy following inadequate non-ra-
diation surgery with positive circumferential resection 
margin13,14. Study reports show that neoadjuvant ther-
apy is less toxic and much more effective than adjuvant 
therapy15-17.  Kapiteijn et al. report that preoperative 
radiotherapy in combination with standardized total 
mesorectal excision reduces the local recurrence rate 
from 8.2% to 2.4% at 2 years5. A study conducted by 
Giusti et al. showed MRI to be very reliable for preop-
erative evaluation of tumor infiltration of mesorectal 
fascia and the authors achieved 100% sensitivity and 
100% specificity, whereas after  adjuvant therapy the 
respective values were 100% and 67%9. Good results 
confirming the role of MRI have been reported in a 
trial performed by Vliegen et al. The authors report 
100% sensitivity and 32%-59% specificity, indicating 
that the influence of post radiation fibrosis on over-
staging led to somewhat lesser specificity18. A recent 
trial indicated the necessity of preoperative irradiation 
in selected patients with positive mesorectal fascia at 
 (a) (b) (c)
Fig. 1. Mesorectal fascia infiltration in rectal carcinoma: (a) sagittal, (b) coronal, and (c) axial T2w scans prior to initia-
tion of neoadjuvant therapy.
 (a)  (b) (c)
Fig. 2. Sagittal (a), coronal (b), and axial (c) T2w scans show regression of rectal carcinoma infiltration of mesorectal 
fascia following neoadjuvant therapy.
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the time of diagnosis19. It can be stated with certainty 
that MRI has emerged as the dominant modality of 
pelvic imaging in rectal cancer and high sensitivity in 
depicting mesorectal fascia20. That is why we used it 
in our study as a reference method for evaluation of 
tumor response of rectal carcinoma following neoad-
juvant therapy. Our results showed tumor regression 
from mesorectal fascia following chemoradiotherapy 
in 70.5% of cases (Wilcoxon test, p=0.002) (Figs. 1 
and 2). In 80.3% of cases, there was a reduction of 
tumor length (Wilcoxon test, p=0.006)  (Figs. 3 and 
4). Our results are comparable to the results reported 
by Topova et al. on 69.5% tumor response to neoad-
juvant therapy21. In our study, the mean tumor length 
prior to neoadjuvant therapy was 5.4 (2.3-15) cm. 
The mean reduction of tumor length following neo-
adjuvant therapy was 3.56 (0.3-4.1) cm. The results 
of our study showed that a large number of patients 
with tumor infiltration of mesorectal fascia benefited 
from neoadjuvant therapy and underwent transition 
from inoperable to operable stage. Unfortunately, 
neoadjuvant therapy is not beneficial for all patients 
due to different tumor response, which is an indepen-
dent prognostic factor for rectal carcinoma22. MRI 
evaluation of rectal carcinoma following neoadjuvant 
therapy proved correct in 100% of the cases regard-
less of post irradiation fibrosis. Despite the known 
limitations created by post irradiation fibrosis, MRI 
is a sovereign modality that enables evaluation of high 
accuracy and topographic relation between lateral ex-
tension of the tumor and mesorectal fascia. MRI is 
very useful for careful selection of patients who will 
benefit from neoadjuvant therapy, and therefore avoid 
inadequate therapy that implies insufficient or exces-
sive medical treatment. 
Conclusion
Magnetic resonance imaging is an important tool 
in the evaluation of tumor infiltration of mesorectal 
fascia, based on which patients are selected for ap-
propriate treatment option for rectal carcinoma. MRI 
 (a) (b)
 (a) (b)
Fig. 3. Sagittal T2w scans: (a) 
initial tumor infiltration of the 
middle portion of rectum; (b) tumor 
regression of the middle portion of 
rectum following chemoradiotherapy.
Fig. 4. Sagittal T2w scans: (a) 
tumor infiltration of the middle 
portion of rectum prior to chemo-
radiotherapy; (b) tumor regression 
of the middle portion of rectum 
after chemoradiotherapy.
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reliably evaluates the effects of neoadjuvant therapy 
which contributes favorably to the outcome of treat-
ment for this disease.
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Sažetak
MAGNETSKA REZONANCIJA ZA PROCJENU UČINKA NEOADJUVANTNE TERAPIJE KOD 
REKTALNOG  KARCINOMA
A. Sofić, Z. Vukobrat-Bijedić, A. Husić-Selimović, N. Šehović, D. Bulja, Dž. Eminagić, M. Banjin i A. Đuran
Iako totalna mezorektalna ekscizija u odnosu na druge kirurške pristupe smanjuje pojavu lokalnog tumorskog recidiva, 
on je još uvijek veoma čest, osobito kada postoji tumorska infiltracija cirkumferentne resekcijske margine. Mezorektalna 
fascija je važan prognostički i dijagnostički čimbenik. Može se reći da mezorektalna fascija predstavlja cirkumferentnu 
resekcijsku marginu ako se kao kirurški pristup koristi totalna mezorektalna ekscizija. Tumorska infiltracija mezorektalne 
fascije zahtijeva prijeoperacijsku neodjuvantnu terapiju kako bi se smanjio rizik od pojave tumorskog recidiva. Cilj ove stu-
dije bio je pokazati važnost visoko rezolucijske fazne magnetske rezonancije (high-resolution phased-array MRI) kao tehni-
ke izbora u prijeoperacijskoj procjeni učinaka neoadjuvantne terapije kod lokalno uznapredovalog rektalnog karcinoma. U 
ovo prospektivno komparativno istraživanje bio je uključen 51 bolesnik s lokalno uznapredovalim rektalnim karcinomom 
koji je infiltrirao mezorektalnu fasciju. Svi bolesnici su podvrgnuti MRI skeniranju dva puta, prije i poslije neoadjuvantne 
radiokemoterapije. Rezultati dobiveni pomoću MRI prije i nakon neoadjuvantne radiokemoterapije uspoređeni su s ci-
ljem  procjene regresije tumorske dužine i regresije tumorske infiltracije mezorektalne fascije. Svi bolesnici s karcinomom 
rektuma koji su podvrgnuti neoadjuvantnoj terapiji imali su podjednaku spolnu distribuciju i prosječnu dob od 51 (32-81) 
godine. MRI rezultati su pokazali da je kod 36 (70,5%) slučajeva nakon radiokemoterapije došlo do povlačenja tumora i 
oslobađanja mezorektalne fascije, pri čemu je Wilcoxonov test pokazao značajne razlike u prijeterapijskom i poslijetera-
pijskom MRI nalazu (Z=-3,162, p=0,002) u smislu regresije tumorske infiltracije mezorektalne fascije. Kod 41 (80,3%) 
bolesnika došlo je do smanjivanja tumorske dužine, pri čemu je Wilcoxonov test  pokazao razlike u prijeterapijskom i 
poslijeterapijskom MRI nalazu (Z=-2,754, p=0,006) u smislu smanjivanja dužine tumora. Prosječna dužina tumora bila je 
5,4 (2,3-15) cm. Prosječno smanjenje dužine tumora nakon radiokemoterapije bilo je 3,56 (0,3-4,1) cm. Poslijeterapijski 
MRI rezultati potvrđeni su patohistološki kod svih 36 bolesnika koji su nakon neoadjuvatntne terapije imali od tumora 
slobodnu mezorektalnu fasciju nakon operacijskog zahvata. MRI je važan u procjeni tumorske infiltracije mezorektalne 
fascije, na osnovi čega se provodi odabir bolesnika za odgovarajući terapijski tretman rektalnog karcinoma. MRI pouzdano 
procjenjuje učinke neoadjuvatne terapije koja utječe na bolji ishod liječenja ove bolesti.
Ključne riječi: Rektalni tumori – terapija; Magnetska rezonancija, snimanje; Neoadjuvantna terapija 
